One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight ...

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen ...

By Maggie Fick, Bhanvi Satija and Patricia Weiss LONDON/FRANKFURT, June 10 (Reuters) - Pfizer is reviewing the timing and ...

The biotech company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry ...

US pharmaceutical giant Pfizer has pulled out of a meeting with German Chancellor Friedrich Merz over plans to reform the ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.

Savvy investors know that change creates opportunities. And a major change is underway at the nation's central bank. Kevin ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.